201 - 225 of 478
Number of results to display per page
TitleDateTypeSetname
201 Real World Experience with Teprotumumab in Patients with Dysthyroid Optic Neuropathy (DON)2023-03-14Textehsl_novel_nam
202 Resection of Extraocular Muscles in Patients with Thyroid Eye Disease2020-03Textehsl_novel_nam
203 Seven Plus Seven Equals Four2020-03Textehsl_novel_nam
204 Severe Heavy Eye Syndrome With Esotropia and Hypertropia in a Female With Congenital Monocular Anophthalmia2022-02Textehsl_novel_nam
205 Smartphone Exophthalmometry With 3D Face Scanners: A Novel Approach to Measure Eyeball Protrusion2021-02Textehsl_novel_nam
206 Some Heads Are Harder Than Others2022-02Image/MovingImageehsl_novel_nam
207 Some Heads Are Harder Than Others2022-02Textehsl_novel_nam
208 Steroid-Resistant Tolosa-Hunt Syndrome Involving Both Orbits and Right Cavernous Sinus in a Nigerian Woman2022-02Textehsl_novel_nam
209 Successful Removal of CSF Shunts in Patients with Idiopathic Intracranial Hypertension2023-03-14Textehsl_novel_nam
210 Successful Treatment of Trigeminal Perineural Invasion by Cutaneous Squamous Cell Carcinoma with Cemiplimab Monotherapy2023-03-14Textehsl_novel_nam
211 Superior Orbital Fissure Syndrome Following Septoplasty2021-02Textehsl_novel_nam
212 Tears for Dinner2022-02Textehsl_novel_nam
213 Tendon-sparing Extraocular Muscle Enlargement and Cranial Nerve Hypertrophy in Chronic Inflammatory Demyelinating Polyneuropathy2022-02Textehsl_novel_nam
214 Teprotumumab Effect on Proptosis, Diplopia and Quality of Life in Active Thyroid Eye Disease (TED) (PDF)2020-03Textehsl_novel_nam
215 Teprotumumab Effect on Proptosis, Diplopia and Quality of Life in Active Thyroid Eye Disease (TED) (Slides)2020-03Textehsl_novel_nam
216 Teprotumumab Effect on Proptosis, Diplopia and Quality of Life in Active Thyroid Eye Disease (TED) (Video)2020-03Image/MovingImageehsl_novel_nam
217 Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results2021-02Image/MovingImageehsl_novel_nam
218 Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results2021-02Textehsl_novel_nam
219 Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results2021-02Textehsl_novel_nam
220 Teprotumumab Treatment in a Patient With Longstanding Thyroid Eye Disease2021-02Textehsl_novel_nam
221 Teprotumumab Treats Sight-Threatening Thyroid Eye Disease2021-02Textehsl_novel_nam
222 Therapeutic Outcomes of Spheno-Orbital Meningiomas and Factors Influencing Recurrence2021-02Textehsl_novel_nam
223 Three Types of Optic Disc Edema in Optic Nerve Sheath Meningioma2021-02Textehsl_novel_nam
224 THRIVE: A Phase 3 Trial of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED)2023-03-14Textehsl_novel_nam
225 Thrombophlebitis-Mediated Polycranial Neuropathy Secondary to Herpes Zoster Ophthalmicus2021-02Textehsl_novel_nam
201 - 225 of 478